North America
https://content.jwplatform.com/videos/yBsz66rH-gJjLxEC2.mp4
Scaling up plans due to new acquisition
$Moneta Porcupine Mines is a gold explorer and mine developer.
The company has six core projects just outside of Timmins Ontario, in
one of the most prolific gold-producing belts in the world.
New Aquisition
Moneta Porcupine Mines recently announced the acquisition of
the O3 Mining Inc.’s assets.
These include the Garrison project, which hosts 2.9 million ounces in
open pit resources.
The acquisition of the O3 assets increases Moneta’s land position by
73%, to create one of the largest undeveloped gold projects in
North America with 4 million indicated and 4.4 million inferred ounces.
Additionally, the acquisition of the O3 Mining Garrison project will
enable Moneta Porcupine Mines to develop
the gold assets on a much larger basis and with a much larger
throughput and a much larger scale of operations.
“We see a lot of upside for our shareholders and we’ll continue to
de-risk and add to the value to our shareholder base,”
says CEO, Chief Geologist & Director, Gary O’Connor.
Well Funded;
$Moneta Porcupine also has the funds to support its drill program this
year, its resource update, and its PEA.
They also have funds to take them through to pre-feasibility next year.
“On top of the cash position of five and a half million,
which we had in our bank at the beginning of this month,
we recently announced the closing
of a 22.6 million dollars financing,
bringing us to over 27 million dollars in cash,”
says O’Connor.
For more information on Moneta Porcupine Mines Inc. (TSX: ME, OTC: MPUCF)
https://content.jwplatform.com/videos/yBsz66rH-gJjLxEC2.mp4
https://videos-fms.jwpsrv.com/0_6039490a_0xf6b79c571db72c43e3fc7f0fc328f8a0c44b7d96/content/conversions/jtUfaVdv/videos/yBsz66rH-3213042.mp4
Recent ME News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:17:11 PM
- 23andMe Launches New Genetic Report on Bipolar Disorder • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- 23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community • GlobeNewswire Inc. • 06/04/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:06:02 PM
- 23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:06:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 09:15:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:07:02 PM
- 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results • GlobeNewswire Inc. • 05/23/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:07:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:06:05 PM
- Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals • GlobeNewswire Inc. • 05/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:06:05 PM
- 23andMe to Report Q4 and Full Year FY2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 08:50:07 PM
- Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case • Business Wire • 04/30/2024 03:00:00 PM
- 23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 04/24/2024 08:05:00 PM
- 23andMe announces CEO’s intention to pursue a potential take-private • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- 23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 04/05/2024 08:05:00 PM
- 23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 • GlobeNewswire Inc. • 03/20/2024 11:30:00 AM
- 23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- 23andMe Launches New Genetic Reports on Common Forms of Cancer • GlobeNewswire Inc. • 03/06/2024 12:30:00 PM
- 23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:36:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:07:48 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM